DA-1726, a dual GLP-1 and glucagon receptor agonist, accumulates preferentially in adipose tissue and liver after subcutaneous administration, with preclinical data supporting a once-weekly dosing schedule. Phase 1 results showed mean waist circumference reduction of 9.8 cm at 8 weeks, positioning the compound as a targeted approach to metabolic dysfunction.
Key Points
- DA-1726 concentrates in adipose and hepatic tissue with prolonged retention
- 48 mg dose produced 9.8 cm mean waist circumference loss in 8 weeks
- Dual GLP-1/glucagon receptor agonism supports glucose control and fat metabolism
Longevity Analysis
Targeted tissue accumulation represents a mechanistic refinement in receptor agonist design, addressing a central problem in metabolic health: localized fat storage that resists conventional interventions. By preferentially concentrating where metabolic dysfunction concentrates—adipose tissue and the liver—DA-1726 may exert more efficient metabolic signaling with reduced systemic exposure, potentially improving the tolerability profile relative to systemic GLP-1 agents. The dual receptor engagement supports both fat mobilization and hepatic glucose handling, two drivers of age-related metabolic decline. Waist circumference reduction specifically signals visceral fat reduction, which carries disproportionate importance for cardiovascular and metabolic risk across the lifespan.
Original published by LT Wire.